

## **Colorado Molecular Correlates Laboratory**

Thoracic Oncology Requisition Form
University of Colorado Denver - Anschutz Medical Campus
12705 E. Montview Blvd., Ste. 400, Aurora, CO 80045 Phone: 303-724-4754 Fax: 303-724-3096 CMOCO@ucdenver.edu



ORDERING PHYSICIAN/LABORATORY			PATIENT INFORMATION (please print)						
			Name (Last, Firs	.t):					
Practice Name:			Patient Address:						
Address:			City:		State:	Zip:			
City:	State: Zip	o:	Phone Number:						
Phone Number:	Fax Number:		Gender:	nale Male	Date of	of Birth:			
Physician's Signature (Required):	Da	ate:	Patient ID:						
☐ Unless checked here order may be modified	based on sample	e quantity & quality.1							
		SPECIMEN IN			-				
Specimen type/collection procedure:			Place of Service  IN-PATIEN	at Time of Collection/O		Collection:	Pate of IP Discharge:		
Materials Sent: Specify Block(s) & Unstained/Stained Slides with their quantity and identifers			Clinical History:			ICD-10 co	ode(s):		
		TF0T 0F	LECTION						
201		TEST SE	LECTION						
LUNG PANEL (all subtypes) <sup>2, 3, 4</sup>   Initial presentation/testing   Mutations: EGFR, KRAS, BRAF, ERBB, Fusions: ALK, ROS1, METex14, NTRK-Amplifications: ERBB2, MET by FISH IHC: PD-L1 (SP263) (if not previously did not previous: EGFR, KRAS, BRAF, ERBB, PLUS kinase domain relevant driver (Ale Fusions: ALK, ROS1, METex14, NTRK, Amplifications: ERBB2, MET by FISH     Relatedness of multiple lesions (multiple nutations: Full panel   If truncal mutation negative, reflex to: Fusions: ALK, ROS1, METex14, NTF, RET     Rapid Panel   Mutations: Rapid EGFR, Rapid KRAS   IHC: ALK, PD-L1 (if not previously done will reflex to initial lung panel if EGFR/ki     Rapid KRAS reflex to panel   Mutations: Rapid KRAS   If negative, will reflex to initial lung panel	1/2/3, RET     lone) 12, METex14 LK, ROS1, RET) a 1/2/3, RET  sle primary vs. m Lesion RK1/2/3,	,		Add-on ge	ERBB3 ERBB4 ERBB4 ESR1 FBXW7 FGFR1 FGFR2 FGFR3 FOXL2 GNA11 GNAQ GNAS H3F3A HNF1A HRAS	☐ IDH1 ☐ IDH2 ☐ KDR ☐ KIT ☐ KRAS ☐ MAP2K1 ☐ MET ☐ MLH1 ☐ NOTCH1 ☐ NRAS ☐ PDGFRA ☐ PIK3CA ☐ PIK3R1 ☐ POLE	☐ PTEN ☐ PTPN11 ☐ RB1 ☐ RET ☐ RHOA ☐ ROS1 ☐ SMAD4 ☐ SMARCB1 ☐ SMO ☐ SRC ☐ STK11 ☐ TERT ☐ TP53 ☐ VHL		
	FR	SIS IHC  ALK (D5F3)  PD-L1  (offered only on NSC	CLC specimens)	(all genes will  NGS Fusion To (all genes will  NGS Mutation	Testing (gene list) be billed/charge esting (gene list) be billed/charge + Fusion Testing be billed/charge sion Testing	d) ) d) g ( <i>gene lis<u>t</u>)</i>			
Please Obtain Pathology Materials (Pathology Report Required, please attach pathology report  Consultation and Report on Referr (surgical pathology consultation for  All tests include physician interpretation and report unless che technical only.  1. If there is insufficient quantity for NGS, target smoking status with a focus on EGFR and KRA 2. Fusions by NGS will be issued in a separate components of testing will not be cancelled unle 3. Only indicated genes will be reported. Select 4. Patients with > 20 pack-years of smoking hist sequentially. If a driver alteration is identified, th performed.  5. If insufficient material for all elements of testir mutation testing prioritized over fusion testing u	red Slides and, or diagnosis) ecked here; contact lab for ted testing for adence. Single gene assay report. If insufficien eas otherwise specificated and on gene if destory may have some the remainder of the lang, step-wise testing	Vor Materials  or service eligibility for  occarcinoma will be based on ys.  at for fusion by NGS, other fied.  sired.  e testing performed requested testing may not be  g will be performed with	Notes/Special	Requests:					

BILLING INFORMATION										
☐ Self-Pay ☐ Insurance	Insured's Relation to Patient: ☐Self	Insurance (For non-University of Colorado Hospital patients, please see below):								
☐ Physician/Lab	Spouse	Insured's Name (if not patient):								
Grant	Dependent									
Claims Address:			City:		State:	Zip:				
Insurance ID#:			Group Name:		Group Number:					
Grant Info (Grant Name, Number, Study Coordinator, PI, and SpeedType):										
BILLING INFORMATION FOR PATIENTS OUTSIDE THE UNIVERSITY OF COLORADO HOSPITAL										
The CY 2018 OPPS/ASC final rule (82 FR 52533-52540) introduced a new exception to current laboratory DOS regulations at 42 CFR 414.510. The new exception permits independent laboratories to bill Medicare directly for molecular pathology tests (CPT codes 81105-81479), which are excluded from the OPPS packaging policy, if the specimen was collected from a hospital outpatient encounter. Payers following this rule include: Medicare, Medicare HMOs, VA and United Healthcare. No such rule has been implemented for specimens collected from hospital inpatients.										
IN-PATIENT STATUS AT TIME OF COLLECTION AND/OR ORDER										
SPECIMENS ORDERED WITHIN 14-DAYS FROM THE DATE OF DISCHARGE: The technical component of any/all services will be billed back to your institution (please provide BILL TO INFORMATION below). The professional interpretation will be billed to insurance.										
SPECIMENS ORDERED 14-DAYS AFTER THE DATE OF DISCHARGE: Any/All services will be billed to insurance.										
OUT-PATIENT STATUS AT TIME OF COLLECTION AND/OR ORDER										
SPECIMENS ORDERED WITHIN 14-DAYS FROM THE DATE OF COLLECTION: The technical components of microdissection (88381), FISH (88271-88275) and IHC (88341-88342,										
88360-88361) will be billed back to your institution (please provide BILL TO INFORMATION below). The professional interpretation will be billed to insurance.  SPECIMENS ORDERED 14-DAYS AFTER THE DATE OF COLLECTION: Any/All services will be billed to insurance.										
SI ECIMENS ORDER	ED 14-DATS AT TEX THE DATE OF	•								
TECHNICAL COMPONENT - BILL TO INFORMATION										
Institution Name:			Billing Person Name:							
Address:										
City:			State:	Zip:						
Phone:			Fax:	•						
Billing Person E-mail:			•							